Adage Capital Partners
CLYM

Adage Capital Partners’s Climb Bio CLYM Stock Holding History

Adage Capital Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.7M Buy
+2,506,000
New +$25.9M 0.05% 372
2024
Q3 		– Sell
-670,362
Closed -$4.77M – 952
2024
Q2 		$4.77M Buy
+670,362
New +$4.46M 0.01% 718

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Adage Capital Partners's CLYM Position: Q2 2026 in Review

Adage Capital Partners opened a new position in Climb Bio (CLYM) in Q2 2026: 2,506,000 shares worth $32.7M. The stake represents 0.05% of the portfolio and ranks #372 among its holdings. This is a return to the name: Adage Capital Partners previously reported a position in CLYM as recently as Q2 2024.

Adage Capital Partners first reported a position in CLYM in Q2 2024 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Adage Capital Partners held 2,506,000 shares of Climb Bio worth $32.7M as of Q2 2026.
  • Climb Bio was a new Adage Capital Partners position in Q2 2026.
  • Climb Bio made up 0.05% of Adage Capital Partners's portfolio in Q2 2026, its #372 holding.
  • Adage Capital Partners first reported a position in Climb Bio in Q2 2024 and has held it in 2 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.